Enzo Biochem, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Supplemental disclosure for statement of cash flows

Supplemental disclosure for statement of cash flows	12 Months Ended
Jul. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	Note 3 - Supplemental disclosure for statement of cash flows In the years ended July 31, 2014, 2013, and 2012, income taxes paid by the Company approximated $44, $46, and $70 respectively. In the years ended July 31, 2014, 2013, and 2012, interest paid by the Company approximated $208, $69, and $5 respectively. During fiscal 2014 and 2013, the Company financed $392 and $365, respectively, in machinery and transportation equipment under installment loans. During fiscal 2014, the Company did not enter into any capital lease agreements. During fiscal 2013, the Company entered into a capital lease for machinery and equipment with a cost basis of $765. During fiscal 2014, the Company recorded $136 in additional paid in capital and reduced accrued liabilities by the same amount for options issued in lieu of cash payment of certain incentive compensation awards.

Supplemental disclosure for statement of cash flows

12 Months Ended

Jul. 31, 2014

Supplemental Cash Flow Elements [Abstract]

Cash Flow, Supplemental Disclosures [Text Block]

Note 3 - Supplemental disclosure for statement of cash flows

In the years ended July 31, 2014, 2013, and 2012, income taxes paid by the Company approximated $44, $46, and $70 respectively.

In the years ended July 31, 2014, 2013, and 2012, interest paid by the Company approximated $208, $69, and $5 respectively.

During fiscal 2014 and 2013, the Company financed $392 and $365, respectively, in machinery and transportation equipment under installment loans.

During fiscal 2014, the Company did not enter into any capital lease agreements. During fiscal 2013, the Company entered into a capital lease for machinery and equipment with a cost basis of $765.

During fiscal 2014, the Company recorded $136 in additional paid in capital and reduced accrued liabilities by the same amount for options issued in lieu of cash payment of certain incentive compensation awards.